Oral factor Xa inhibitor apixaban – more effective than enoxaparin for thromboprophylaxis after knee replacement - medical center information, medical center, health care, disease, medical journal

Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin.

The primary outcome in this Lancet study was the composite of asymptomatic and symptomatic deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE), and all-cause death during treatment. The primary outcome was reported in 15% of apixaban patients and 24% of enoxaparin patients (relative risk 0·62), absolute risk reduction 9·3%.

Related Posts

• Friston is Freudian
• Quintiles to More Heavily Directly Invest in the Drugs Which it Evaluates - But Not to Worry, Says an Expert?
• Toasted at the Lean Conference
• First official antismoking campaign was launched in 1604 by James I of England
• Unneccesary Medical Tests: Tort Reform Can't Solve it All
• Color Atlas of Pathophysiology, 1st ed. 2000
• Video: A life cycle in 90 seconds
• Standardized patient: Over the course of three days, I had 23 head-to-toe physicals from 23 medical students
• Stop Medical Malpractice: The White Coat Wall of Silence
• Pediatric and Adolescent Gynecology, 5th ed. 2005
• I was not skeptical enough
• A Bayesian Brain is a Freudian Brain
• Old drug, new warnings: Acetaminophen (paracetamol, Tylenol)
• EHRevent.org and "The National Database of EHR Errors Being Called For" - Where's the Beef?
• No way to run a hospital